Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229-63.
DOI: 10.3322/caac.21834
Siegel RL, Tyler Kratzer B, Giaquinto AN, et al. Cancer statistics, 2025. 2025 [cited 2025 Apr 1]. Available from: https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21871
DOI: 10.3322/caac.21871
Rahib L, Wehner MR, Matrisian LM, et al. Estimated Projection of US Cancer Incidence and Death to 2040. JAMA Netw Open 2021;4(4):e214708-e214708 [citado: 19 de marzo de 2025].
DOI: 10.1001/jamanetworkopen.2021.4708
Fitzmaurice C, Akinyemiju T, Abera S, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results from the Global Burden of Disease Study 2015. JAMA Oncol 2017;3(12):1683-91 [citado: 20 de marzo de 2025].
Liu Y, Zheng J, Hao J, et al. Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019. Cancer Med 2022;11(5):1310-23.
DOI: 10.1002/cam4.4551
Younossi ZM, Wong G, Anstee QM, et al. The Global Burden of Liver Disease. Clin Gastroenterol Hepatol 2023;21(8):1978-91.
DOI: 10.1016/j.cgh.2023.04.015
Vogel A, Chan SL, Dawson LA, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2025;0(0) [citado el 19 de marzo de 2025].
Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69(1):182-236.
DOI: 10.1016/j.jhep.2018.03.019
Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37(2):429-42 [citado el 21 de marzo de 2025].
DOI: 10.1053/jhep.2003.50047
Sangro B, Kudo M, Erinjeri JP, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet 2025;405(10474):216-32 [citado el 3 de abril de 2025].
Kudo M, Ren Z, Guo Y, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. The Lancet 2025;405(10474):203-15 [citado el 2 de abril de 2025].
DOI: 10.1016/S0140-6736(24)02575-3
Yang Y, Si T. Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Biol Med 2018;15(3):299-310 [citado el 24 de marzo de 2025].
DOI: 10.20892/j.issn.2095-3941.2017.0177
Salem R, Johnson GE, Kim E, et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology 2021;74(5):2342-52 [citado el 24 de marzo de 2025].
DOI: 10.1002/hep.31819
Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nature Reviews Clinical Oncology 2018;15(10):599-616 [citado el 21 de marzo de 2025].
DOI: 10.1038/s41571-018-0073-4
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in Advanced Hepatocellular Carcinoma. NEJM 2008;359;378-90 [cited 2025 Mar 22].
DOI: 10.1056/NEJMoa0708857
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1):25-34.
DOI: 10.1016/S1470-2045(08)70285-7
Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial. J Clin Oncol 2013;31(32):4067-75 [citado el 28 de marzo de 2025].
DOI: 10.1200/JCO.2012.45.8372
Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study. J Clin Oncol 2013;31(28):3517-24 [citado el 28 de marzo de 2025].
Cainap C, Qin S, Huang WT, et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial. J Clin Oncol 2015;33(2):172-9 [citado el 28 de marzo de 2025].
DOI: 10.1200/JCO.2013.54.3298
Zhu AX, Rosmorduc O, Evans TRJ, et al. Search: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015;33(6):559-66 [citado el 28 de marzo de 2025].
DOI: 10.1200/JCO.2013.53.7746
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391(10126):1163-73 [citado el 27 de marzo de 2025].
DOI: 10.1016/S0140-6736(18)30207-1
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New Engl J Med 2020;382(20):1894-905 [citado el 22 de marzo de 2025].
DOI: 10.1056/NEJMoa1915745
Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evidence 2022;1(8) [citado el 22 de marzo de 2025].
DOI: 10.1056/EVIDoa2100070
Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Articles Lancet Oncol 2021;22:977-90 [citado el 28 de marzo de 2025].
DOI: 10.1016/S1470-2045(21)00252-7
Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. The Lancet 2023;402(10408):1133-46 [citado el 22 de marzo de 2025].
Galle PR, Decaens T, Kudo M, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. J Clin Oncol 2024;42(Suppl.17):LBA4008-LBA4008 [citado el 22 de marzo de 2025].
DOI: 10.1200/JCO.2024.42.17_suppl.LBA4008
Kudo M, Yau T, Decaens T, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses. J Clin Oncol 2025;43(Suppl.4):520-520 [citado el 22 de marzo de 2025].
DOI: 10.1200/JCO.2025.43.4_suppl.520
Rose MG, Kennedy EB, Abou-Alfa GK, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights. JCO Oncol Pract 2024;20(8):1035-9 [citado el 29 de marzo de 2025].
DOI: 10.1200/OP.24.00189
Qin S, Kudo M, Meyer T, et al. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2023;9(12):1651-9 [citado el 22 de marzo de 2025].
DOI: 10.1001/jamaoncol.2023.4003
Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2017;389(10064):56-66.
DOI: 10.1016/S0140-6736(16)32453-9
Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018;379(1):54-63 [citado el 22 de marzo de 2025].
DOI: 10.1056/NEJMoa1717002
Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(2):282-96 [citado el 22 de marzo de 2025].
Chan SL, Ryoo BY, Mo F, et al. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment. J Hepatol 2024;81(2):258-64 [citado el 31 de marzo de 2025].
DOI: 10.1016/j.jhep.2024.03.033
Yoo C, Cheon J, Ryoo BY, et al. Second-line regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) after progression on first-line atezolizumab plus bevacizumab (Atezo-Bev): Phase 2 REGONEXT trial. J Clin Oncol 2024;42(Suppl.3):477-477 [citado el 31 de marzo de 2025].
DOI: 10.1200/JCO.2024.42.3_suppl.477
Yoo C, Kim HD, Chon HJ, et al. LBA1 Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab (KCSG HB23-04). Ann Oncol 2024;35:S1450 [citado el 23 de marzo de 2025].
DOI: 10.1016/j.annonc.2024.10.149
Roessler D, Öcal O, Philipp AB, et al. Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study. J Cancer Res Clin Oncol 2023;149(7):3065-73 [citado el 29 de marzo de 2025].
DOI: 10.1007/s00432-022-04206-8
Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10(7):505-14 [citado el 27 de marzo de 2025].
DOI: 10.1038/nrc2868
Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 2014;6(1) [citado el 26 de marzo de 2025].
DOI: 10.1186/2045-824X-6-18
Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer 2008;8(8):592-603 [citado el 26 de marzo de 2025].
DOI: 10.1038/nrc2442
Kudo M. Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma. Liver Cancer 2018;7:1-19 [citado el 27 de marzo de 2025].
DOI: 10.1159/000487148
Ikeda M, Okusaka T, Mitsunaga S, et al. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2016;22(6):1385-94 [citado el 27 de marzo de 2025].
DOI: 10.1158/1078-0432.CCR-15-1354
Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017;52(4):512-9 [citado el 27 de marzo de 2025].
DOI: 10.1007/s00535-016-1263-4
Llovet JM, Kudo M, Merle P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol 2023;24(12):1399-410 [citado el 31 de marzo de 2025].
Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021;592(7854):450-6 [citado el 3 de abril de 2025].
Rimini M, Kudo M, Tada T, et al. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open 2021;6(6):100330 [citado el 3 de abril de 2025].
DOI: 10.1016/j.esmoop.2021.100330
Rimini M, Rimassa L, Ueshima K, et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open 2022;7(6) [citado el 3 de abril de 2025].
Número de descargas:
61
Número de visitas:
22
Citas:
0
